RAPT Therapeutics RAPT Stock
RAPT Therapeutics Price Chart
RAPT Therapeutics RAPT Financial and Trading Overview
| RAPT Therapeutics stock price | 7.67 USD |
| Previous Close | 21.1 USD |
| Open | 22.1 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 20.69 - 22.1 USD |
| 52 Week Range | 14.86 - 32.45 USD |
| Volume | 372.79K USD |
| Avg. Volume | 360.64K USD |
| Market Cap | 742.2M USD |
| Beta (5Y Monthly) | 0.364123 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.89 USD |
RAPT Valuation Measures
| Enterprise Value | 519.09M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.355882 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 837.6924 |
| Price/Book (mrq) | 3.3608088 |
| Enterprise Value/Revenue | 585.884 |
| Enterprise Value/EBITDA | -5.436 |
Trading Information
RAPT Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.364123 |
| 52-Week Change | 29.71% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 32.45 USD |
| 52 Week Low | 14.86 USD |
| 50-Day Moving Average | 19.4 USD |
| 200-Day Moving Average | 22.04 USD |
RAPT Share Statistics
| Avg. Volume (3 month) | 360.64K USD |
| Avg. Daily Volume (10-Days) | 289.99K USD |
| Shares Outstanding | 34.35M |
| Float | 28.72M |
| Short Ratio | 10.61 |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 97.60% |
| Shares Short | 3.11M |
| Short % of Float | 12.28% |
| Short % of Shares Outstanding | 9.07% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10900.67% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.69% |
| Return on Equity (ttm) | -47.71% |
Income Statement
| Revenue (ttm) | 886K USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.53M USD |
| EBITDA | -95495000 USD |
| Net Income Avi to Common (ttm) | -92641000 USD |
| Diluted EPS (ttm) | -2.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 231.63M USD |
| Total Cash Per Share (mrq) | 6.74 USD |
| Total Debt (mrq) | 8.53M USD |
| Total Debt/Equity (mrq) | 3.87 USD |
| Current Ratio (mrq) | 10.856 |
| Book Value Per Share (mrq) | 6.43 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -73795000 USD |
| Levered Free Cash Flow (ttm) | -39927500 USD |
Profile of RAPT Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 561 Eccles Avenue |
| ZIP | 94080 |
| Phone | 650 489 9000 |
| Website | https://www.rapt.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 111 |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Q&A For RAPT Therapeutics Stock
What is a current RAPT stock price?
RAPT Therapeutics RAPT stock price today per share is 7.67 USD.
How to purchase RAPT Therapeutics stock?
You can buy RAPT shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RAPT Therapeutics?
The stock symbol or ticker of RAPT Therapeutics is RAPT.
Which industry does the RAPT Therapeutics company belong to?
The RAPT Therapeutics industry is Biotechnology.
How many shares does RAPT Therapeutics have in circulation?
The max supply of RAPT Therapeutics shares is 41.7M.
What is RAPT Therapeutics Price to Earnings Ratio (PE Ratio)?
RAPT Therapeutics PE Ratio is now.
What was RAPT Therapeutics earnings per share over the trailing 12 months (TTM)?
RAPT Therapeutics EPS is -3.05 USD over the trailing 12 months.
Which sector does the RAPT Therapeutics company belong to?
The RAPT Therapeutics sector is Healthcare.
RAPT Therapeutics RAPT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}